Methods of treating autoimmune diseases with anti-FcεRI antibodies
View Patent ↗Methods of using anti-FceRI or anti-IgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use in treating an autoimmune disease. Also disclosed are non-antibody compounds that specifically activate basophils and/or mast cells, either by cross-linking IgE or FceRI, or by activating the cells through an FceRI-independent pathway and methods of using the same to treat autoimmune diseases.
1. A method of treating a Th1-mediated autoimmune disease in a subject, the method comprising administering to the subject an effective amount of an antibody, or antigen-binding fragment thereof, that binds to the Fc epsilon receptor I (FcεRI), thereby treating the Th1-mediated autoimmune disease, and wherein the antibody is administered in an amount sufficient to crosslink the FcεRI on basophils and/or mast cells, thereby activating the basophils and/or mast cells.
2. The method of claim 1 , wherein the antibody is a mononclonal antibody.
3. The method of claim 1 , wherein the antibody is a chimeric antibody, a humanized antibody, or a human antibody.
4. The method of claim 1 , wherein the antibody is an IgG antibody.
5. The method of claim 1 , wherein the antibody is an IgE antibody.
6. The method of claim 1 , wherein the FcεRI is a human FcεRI.
7. The method of claim 1 , wherein the Th1-mediated autoimmune disease is selected from the group consisting of type 1 insulin-dependent diabetes mellitus, scleroderma, multiple sclerosis, posterior uveitis, Crohn's disease, inflammatory bowel disease, and rheumatoid arthritis.
8. The method of claim 1 , wherein the subject is a mammal.
9. The method of claim 1 , wherein the subject is a human.
10. The method of claim 1 , wherein the antibody is administered chronically to the subject.
11. The method of claim 10 , wherein the antibody is administered to the subject every week for at least 10 weeks.
12. The method of claim 10 , wherein the antibody is administered to the subject one or more times per day for at least five consecutive days.